Is IPSC or LIXT more profitable?

Century Therapeutics' return on equity of -49.89% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.89% -37.42% Lixte Biotechnology N/A -134.91% -95.61%

Do analysts recommend XFOR or LIXT?

X4 Pharmaceuticals currently has a consensus price target of $9.38, suggesting a potential upside of 127.00%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer XFOR or LIXT?

In the previous week, X4 Pharmaceuticals had 4 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 1 mentions for Lixte Biotechnology. X4 Pharmaceuticals' average media sentiment score of 0.17 beat Lixte Biotechnology's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LIXT or AGMB?

AgomAb Therapeutics has a consensus target price of $32.75, suggesting a potential upside of 158.89%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AgomAb Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has preferable earnings & valuation, LIXT or AGMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A AgomAb Therapeutics N/A N/A N/A N/A N/A

Is LIXT or AGMB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% AgomAb Therapeutics N/A N/A N/A

Does the media prefer LIXT or AGMB?

In the previous week, AgomAb Therapeutics had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 1 mentions for Lixte Biotechnology. AgomAb Therapeutics' average media sentiment score of 0.40 beat Lixte Biotechnology's score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, EPRX or LIXT?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A

Is EPRX or LIXT more profitable?

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% Lixte Biotechnology N/A -134.91% -95.61%

Do analysts recommend LIXT or CGC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17

Does the media favor LIXT or CGC?

In the previous week, Canopy Growth had 8 more articles in the media than Lixte Biotechnology. MarketBeat recorded 9 mentions for Canopy Growth and 1 mentions for Lixte Biotechnology. Canopy Growth's average media sentiment score of 0.33 beat Lixte Biotechnology's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Lixte Biotechnology (LIXT) Competitors

$7.21 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$7.51 +0.30 (+4.16%)

As of 07/2/2026 07:46 PM Eastern

Compare

LIXT vs. IPSC, XFOR, AGMB, EPRX, and CGC

Should you buy Lixte Biotechnology stock or one of its competitors? MarketBeat compares Lixte Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lixte Biotechnology include Century Therapeutics (IPSC), X4 Pharmaceuticals (XFOR), AgomAb Therapeutics (AGMB), Eupraxia Pharmaceuticals (EPRX), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry.

How does Lixte Biotechnology compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Lixte Biotechnology has lower revenue, but higher earnings than Century Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	4.01	-$9.58M	-$1.14	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Century Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 95.47%. Given Century Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Century Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lixte Biotechnology had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 1 mentions for Lixte Biotechnology and 0 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.00 equaled Lixte Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Century Therapeutics	Neutral
Lixte Biotechnology	Neutral

Century Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Century Therapeutics' return on equity of -49.89% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.89%	-37.42%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Summary

Century Therapeutics beats Lixte Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Lixte Biotechnology compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

X4 Pharmaceuticals currently has a consensus price target of $9.38, suggesting a potential upside of 127.00%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

X4 Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, X4 Pharmaceuticals had 4 more articles in the media than Lixte Biotechnology. MarketBeat recorded 5 mentions for X4 Pharmaceuticals and 1 mentions for Lixte Biotechnology. X4 Pharmaceuticals' average media sentiment score of 0.17 beat Lixte Biotechnology's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lixte Biotechnology has lower revenue, but higher earnings than X4 Pharmaceuticals. Lixte Biotechnology is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$9.01M	43.22	-$79.20M	-$4.54	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Lixte Biotechnology has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Summary

X4 Pharmaceuticals beats Lixte Biotechnology on 10 of the 15 factors compared between the two stocks.

How does Lixte Biotechnology compare to AgomAb Therapeutics?

Lixte Biotechnology (NASDAQ:LIXT) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

5.1% of Lixte Biotechnology shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, AgomAb Therapeutics had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 4 mentions for AgomAb Therapeutics and 1 mentions for Lixte Biotechnology. AgomAb Therapeutics' average media sentiment score of 0.40 beat Lixte Biotechnology's score of 0.00 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics' return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
AgomAb Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

AgomAb Therapeutics has a consensus target price of $32.75, suggesting a potential upside of 158.89%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

AgomAb Therapeutics beats Lixte Biotechnology on 7 of the 9 factors compared between the two stocks.

How does Lixte Biotechnology compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Eupraxia Pharmaceuticals presently has a consensus target price of $18.00, suggesting a potential upside of 169.06%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lixte Biotechnology had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 1 mentions for Lixte Biotechnology and 0 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.00 equaled Lixte Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Neutral
Lixte Biotechnology	Neutral

5.1% of Lixte Biotechnology shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eupraxia Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Summary

Eupraxia Pharmaceuticals beats Lixte Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Lixte Biotechnology compare to Canopy Growth?

Lixte Biotechnology (NASDAQ:LIXT) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Lixte Biotechnology has a net margin of 0.00% compared to Canopy Growth's net margin of -75.27%. Canopy Growth's return on equity of -26.95% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Canopy Growth	-75.27%	-26.95%	-17.20%

Lixte Biotechnology has higher earnings, but lower revenue than Canopy Growth. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Canopy Growth	$251.01M	1.79	-$190.29M	-$0.59	N/A

In the previous week, Canopy Growth had 8 more articles in the media than Lixte Biotechnology. MarketBeat recorded 9 mentions for Canopy Growth and 1 mentions for Lixte Biotechnology. Canopy Growth's average media sentiment score of 0.33 beat Lixte Biotechnology's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Canopy Growth	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lixte Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Canopy Growth beats Lixte Biotechnology on 9 of the 14 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIXT vs. The Competition

Export

Metric	Lixte Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$108.29M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-6.38	21.61	28.02	24.70
Price / Sales	N/A	339.42	538.82	97.75
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	6.87	8.66	10.96	6.46
Net Income	-$6.01M	$23.81M	$3.57B	$337.01M
7 Day Performance	0.28%	3.39%	2.12%	1.69%
1 Month Performance	3.00%	10.81%	5.25%	3.81%
1 Year Performance	174.25%	62.61%	33.29%	23.90%

Lixte Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIXT Lixte Biotechnology	0.2647 of 5 stars	$7.21 flat	N/A	+174.2%	$108.29M	N/A	N/A	4	Gap Up
IPSC Century Therapeutics	1.4069 of 5 stars	$2.39 -2.4%	$4.75 +98.7%	+333.9%	$441.87M	$109.16M	N/A	170
XFOR X4 Pharmaceuticals	2.8982 of 5 stars	$4.09 -12.4%	$9.38 +129.2%	+110.2%	$440.47M	$35.11M	N/A	80	News Coverage
AGMB AgomAb Therapeutics	N/A	$11.87 -8.6%	$32.75 +175.9%	N/A	$430.13M	N/A	N/A	62
EPRX Eupraxia Pharmaceuticals	2.011 of 5 stars	$6.71 +1.5%	$18.00 +168.3%	+22.4%	$429.77M	N/A	N/A	29	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIXT) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lixte Biotechnology (LIXT) Competitors

LIXT vs. IPSC, XFOR, AGMB, EPRX, and CGC

How does Lixte Biotechnology compare to Century Therapeutics?

Summary

How does Lixte Biotechnology compare to X4 Pharmaceuticals?

Summary

How does Lixte Biotechnology compare to AgomAb Therapeutics?

Summary

How does Lixte Biotechnology compare to Eupraxia Pharmaceuticals?

Summary

How does Lixte Biotechnology compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lixte Biotechnology (LIXT) Competitors

LIXT vs. IPSC, XFOR, AGMB, EPRX, and CGC

How does Lixte Biotechnology compare to Century Therapeutics?

Which has better valuation & earnings, IPSC or LIXT?

Do analysts recommend IPSC or LIXT?

Does the media prefer IPSC or LIXT?

Which has more volatility & risk, IPSC or LIXT?

Do insiders and institutionals believe in IPSC or LIXT?

Is IPSC or LIXT more profitable?

Summary

How does Lixte Biotechnology compare to X4 Pharmaceuticals?

Do analysts recommend XFOR or LIXT?

Which has more volatility and risk, XFOR or LIXT?

Do institutionals and insiders hold more shares of XFOR or LIXT?

Does the media prefer XFOR or LIXT?

Which has preferable valuation & earnings, XFOR or LIXT?

Is XFOR or LIXT more profitable?

Summary

How does Lixte Biotechnology compare to AgomAb Therapeutics?

Do institutionals & insiders hold more shares of LIXT or AGMB?

Does the media prefer LIXT or AGMB?

Is LIXT or AGMB more profitable?

Which has preferable earnings & valuation, LIXT or AGMB?

Do analysts recommend LIXT or AGMB?

Summary

How does Lixte Biotechnology compare to Eupraxia Pharmaceuticals?

Do analysts recommend EPRX or LIXT?

Does the media favor EPRX or LIXT?

Do institutionals and insiders hold more shares of EPRX or LIXT?

Which has more volatility and risk, EPRX or LIXT?

Is EPRX or LIXT more profitable?

Which has higher earnings & valuation, EPRX or LIXT?

Summary

How does Lixte Biotechnology compare to Canopy Growth?

Is LIXT or CGC more profitable?

Which has better earnings & valuation, LIXT or CGC?

Does the media favor LIXT or CGC?

Which has more risk and volatility, LIXT or CGC?

Do analysts recommend LIXT or CGC?

Do institutionals & insiders believe in LIXT or CGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools